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Abstract
Background: The Hepatitis B Virus X protein (HBx) plays a major role in hepatocellular carcinoma (HCC)
development, however, its contribution to tumor invasion and metastasis has not been established so far. Heat
shock protein 90 alpha (HSP90alpha) isoform is an ATP-dependent molecular chaperone that maintains the active
conformation of client oncoproteins in cancer cells, which is abundantly expressed in HCC, especially in hepatitis B
virus (HBV)-related tumors, might be involved in tumor progression.
Methods: The levels of HSP90alpha, extracellular signal-regulated kinase 1/2 (ERK1/2), phosphorylated ERK1/2 (p-
ERK1/2) and c-Myc in HBx-transfected HepG2 cells were determined by western blots analysis. The endogenous
ERKs activity was demonstrated by ELISA assay. The regulation of c-Myc-mediated HSP90 alpha promoter
transactivation by HBx was evaluated through electrophoretic mobility shift analysis (EMSA). The c-Myc-mediated
HSP90alpha transcription was analysed by promoter assay. The HBx-expressing cells were transfected with specific
small interference RNA (siRNA) against c-Myc. The in vitro invasion potentials of cells were evaluated by Transwell
cell invasion assay.
Results: HBx induces HSP90alpha expression at the transcription level. The induction effect of HBx was inhibited
after treatment with c-Myc inhibitor, 10058-F4. In addition, the luciferase activity of the HSP90alpha promoter
analysis revealed that the HBx is directly involved in the c-Myc-mediated transcriptional activation of HSP90alpha.
Furthermore, HBx induces c-Myc expression by activation of Ras/Raf/ERK1/2 cascades, which in turn results in
activation of the c-Myc-mediated HSP90alpha promoter and subsequently up-regulation of the HSP90alpha
expression. Overexpression of HSP90alpha in HBx-transfected cells enhances tumor cells invasion. siRNA-mediated
c-Myc knockdown in HBx-transfected cells significantly suppressed HSP90alpha expression and cells invasion in
vitro.
Conclusion: These results demonstrate the ability of HBx to promote tumor cells invasion by a mechanism
involving the up-regulation of HSP90alpha and provide new insights into the mechanism of action of HBx and its
involvement in tumor metastasis and recurrence of HCC.
Background
Hepatitis B virus (HBV) is strongly associated with the
development of hepatocellular carcinoma (HCC) [1].
One of the open-reading frames encoded by the HBV
genome is an oncogenic X protein (HBx), which is the
most frequently integrated viral sequence found in
HCCs. HBx is likely to be implicated in the several
different steps of carcinoma development. Most efforts
i nt h es t u d yo ft h er o l eo fH B xi nH C Cd e v e l o p m e n t
have focused on its involvement in the genesis of liver
carcinomas. In this regard, HBx is able to induce HCC
either alone or in synergy with c-Myc or chemical carci-
nogens in transgenic mice [2,3]. Although it does not
bind directly to DNA, HBx affects transcriptional activa-
tion via its interaction with nuclear transcription factors
and the cytoplasmic modulation of signal transduction
pathways. HBx activates several signal transduction
pathways that lead to the transcriptional upregulation of
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factors and oncogenes [4]. In addition, HBx promotes
cell cycle progression, inactivates negative growth regu-
lators like p53 [5] and facilitates the accumulation of
DNA mutations by interfering with the DNA repair
machinery [6]. HBx is also able to interfere with apopto-
tic signals, leading to tumor cell survival, although this
issue remains controversial [7].
Recently, several reports have demonstrated that HBx
is also implicated in the late stages of tumor progres-
sion, metastasis and angiogenesis. HBx induces extensive
morphological changes and cytoskeleton rearrangements
in liver cells [8]. It induces adherens junction disruption
[9] and modulates integrin-mediated adhesion to extra-
cellular matrix (ECM) [10]. In addition, HBx promotes
tumor cell invasion by inducing membrane-type matrix
metalloproteinase 1 (MT1-MMP) [11], MMP-9 [12] and
urokinase-type plasminogen activator [13] or reducing
E-cadherin [14]. Also, HBx activates hypoxia-inducible
factor-1a, which promotes angiogenesis through activa-
tion of several angiogenic factors like vascular endothe-
lial growth factor [15]. However, the role of HBx in
tumor invasion and metastasis and the underlying
mechanisms are far from being fully understood.
Heat shock protein 90 (HSP90) is an important mole-
cular chaperone and have key roles in signal transduc-
tion, protein folding, protein degradation, and
morphological evolution [16]. The HSP90 is abundantly
expressed by a variety of tumor types and has been
recently targeted for cancer therapy [17]. Recently, sev-
eral reports have shown that HSP90alpha isoform is
associated with the invasive and metastatic abilities of
the human breast cancer cells. Cell-surface HSP90alpha
is involved in heregulin-induced the receptor tyrosine
kinase HER-2 activation and signaling, leading to cytos-
keletal rearrangement, essential for cell invasion [18,19].
The extracellular hyperacetylated HSP90alpha promotes
extracellular maturation of MMP-2, involved in tumor
invasion and metastasis [20,21]. As a result of this the
overexpression of HSP90alpha is common in various
human tumours, preferentially in malignant cancers,
correlates with poor prognosis and resistance to therapy
[22]. Owing to its key role in the activity of various
oncogenic proteins and pathways, HSP90alpha may play
au n i q u er o l ei nt u m o rm e t a s t a s i s .I m m u n o h i s t o c h e m -
ical studies of HSP90alpha expression in HBV-related
HCC demonstrated significant upregulation of HSP90al-
pha in the tumor tissue compared with adjacent nontu-
mor tissues [23]. Recently, we have shown that
HSP90alpha is upregulated in the HBxpositive HepG2
cells compared with HBx-negative HepG2 cells by pro-
teomic analysis [24]. However, the underlying mechan-
ism for the HSP90alpha activition in HBV induced HCC
is still unknown.
In this study, we demonstrate that HBx induces c-Myc
expression by activation of Ras/Raf/ERK1/2 pathway,
which in turn results in activation of the c-Myc-
mediated HSP90alpha promoter and subsequently up-
regulation of the HSP90alpha expression. Moreover,
Overexpression of HSP90alpha in HBx-transfected cells
enhances tumor cells invasion. Repression of endogen-
ous c-Myc expression by siRNA significantly reduces
HSP90alpha expression and the invasive capacity of
HBx-transfected cells. These results demonstrate that
HBx has an effect on the up-regulation of the HSP90
alpha, which is associated with tumor cells invasion and
support a role for HBx in the late steps of tumor devel-
opment and metastasis.
Results
HBx upregulates HSP90alpha expression
The up-regulation of HSP90alpha is implicated in the
malignant progression of HCCs, especially in HBV-
related tumors [16,23]. However, the viral factor respon-
sible for this phenomenon is unknown. Therefore, we
first investigated whether HSP90alpha expression is acti-
vated by HBx in cultured human liver cells. For this
purpose, we transiently transfected HBxexpressing plas-
mid, pcDNA3-X, into a human hepatoma cell line
HepG2. As a result, the HSP90alpha protein level was
increased by HBx in a dose-dependent manner, as deter-
mined by Western blot analyses (Figure 1A). The level
of HSP90alpha mRNA in HepG2-pcDNA3-X cells, as
determined by semiquantitative RT-PCR, was similarly
increased by HBx (Figure 1B), which suggests that HBx
increases HSP90alpha expression at the transcription
level. Furthermore, to investigate the effect of HBx on
the HSP90alpha promoter activity, we performed lucifer-
ase assay, using the HSP90alpha-luciferase reporter
(HSP90a-Luc1430) that contains luciferase gene under
the control of full-length HSP90alpha promoter. As a
result, we found that HBx specifically activates the
HSP90alpha promoter activity in a dose-dependent
manner, up to approx ~2.5-fold (Figure 1C). Therefore,
we confirm that HBx upregulates HSP90alpha expres-
sion at the transcription initiation step by modulating
its promoter activity.
HBx upregulates HSP90alpha expression by
activating c-Myc
It is well known that HBx mediates the activation of sig-
nal transduction pathways such as the Ras/Raf/ERK1/2
cascades, leading to the induction of c-myc [25]. To
investigate HBx activates c-Myc expression via the Ras/
Raf/ERK1/2 pathway, we first detected the protein levels
of c-Myc, ERK1/2 and phosphorylation of ERK-1/2 in
HepG2-pcDNA3 and HepG2-pcDNA3-X cells by wes-
tern blot analysis. As shown in Figure 2A, the
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ERK-1/2 were increased in the HepG2-pcDNA3-X cells
was compared with HepG2-pcDNA3 cells. Futhermore,
the c-Myc, ERK1/2 and phosphorylation of ERK-1/2
were decreased in HepG2-pcDNA3-X cells treated with
U0126, a known ERKs inhibitor (Figure 2A). These
results show that HBx activates the c-Myc protein
through the Ras/Raf/ERK1/2 pathway.
It is reported that the upstream portion of the
HSP90alpha gene contains a c-Myc binding element,
which this element is required for the inducible transac-
tivation of HSP90alpha by c-Myc, and that HSP90alpha
mRNA and protein levels are also elevated in response
to c-Myc induction [26]. Therefore, we next tried to
investigate whether the up-regulation of HSP90alpha
expression in the HBx-expressing cells is due to
enhanced expression of c-Myc or not. Both mRNA and
protein levels of c-Myc were significantly increased in
the HBx-expressing cells (Figure 2B and 2C, respec-
tively), which suggests that HBx induces the expression
of c-Myc by stimulating its transcription. Treatment of
the HBx-expressing cells with the c-Mycspecific inhibi-
tor 10058-F4 resulted in a significantly decreased of
both mRNA and protein levels of HSP90alpha (Figure
2B and 2C), suggesting that 10058-F4 blocked the
induction of HSP90alpha activation by HBx.
To provide a more direct evidence for the role of c-
Myc in the regulation of HSP90alpha gene by HBx, we
Figure 1 Upregulation of Hsp90a expression by HBx. (A) HepG2 cells were transiently transfected with the indicated amount (1 μg, 2 μg, 3
μg) of pcDNA3-X and Western blotting of HSP90a was performed. (B) Total RNA purified from the HBxtransfected HepG2 cells was subjected to
RT-PCR for measuring HSP90a transcripts. (C) Increasing amount (1 μg, 2 μg, 3 μg) of pcDNA3-X was cotransfected with 2 μg of HSP90a
promoter-luciferase reporter constructs (Hsp90a-Luc1430), and 2 μgo fb-galactosidase reporter plasmid into HepG2 cells and luciferase assay
was performed. Luciferase activity was normalized with the b-alactosidase activity in cell lysate. Error bars indicate standard deviations (SD)
obtained from three different experiments prepared in triplicate.
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cing a specific siRNA into HBx-expressing cells. As
expected, c-Myc expression was specifically decreased
by c-Myc siRNA in a dose-dependent manner (Figure
2D). Accordingly, HSP90alpha expression was decreased,
proving that c-Myc plays a direct role in the induction
of HSP90alpha expression by HBx.
Transactivation of the HSP90alpha promoter by HBx
through the c-Myc-binding site
To investigate whether the transcriptional activity of
HSP90alpha is regulated by HBx through the c-Myc
binding site, the promoter activity of the HSP90alpha
g e n ew a se x a m i n e d .A ss h o w ni nF i g u r e3 A ,w ec o n -
structed a reporter vector (HSP90 a-Luc1430)containing
segments of the 5’ flanking region and part of the exon
1 of the HSP90alpha gene, including an E-box site
(CACGTG) in the proximal promoter, linked to the pro-
moter coding domain of the luciferase reporter gene
(pGL3-luc). In addition, to determine whether the E-box
site (CACGTG) was responsible for c-Mycmediated acti-
vation, its sequence was changed from CACGTG to
CACCTG using site directed mutagenesis, a reporter
vector (HSP90alpha-Luc1430Mut) was constructed.
These plasmids were cotransfected into HepG2 cells
with the pcDNA3 or the pcDNA3-X vectors. As shown
in Figure 3B, the luciferase activity of the HSP90alpha-
Luc1430 cotransfected with pcDNA3-X was ~5.0-fold
higher than those for the pGL3-Luc and the HSP90al-
pha-Luc1430 cotransfected with pcDNA3 or without the
vector. However, the luciferase activity remained essen-
tially unchanged, when the pGL3-Luc and the HSP90al-
pha-Luc1430Mut were cotransfected with pcDNA3-X,
pcDNA3, or without the vector into HepG2 cells,
respectively. The results showed that the luciferase
activity of the HSP90alpha promoter containing the c-
Myc binding element was significantly increased in
HBx-transfected cells, compared with HepG2 and
HepG2-pcDNA3 cells, thus indicating that the E-box in
the promoter region of the HSP90alpha gene mediates
transcriptional activation by c-Myc.
To additionally confirm that HBx is directly involved in
the c-Myc-mediated transcriptional activation of
HSP90alpha, we examined whether HBx is correlated to
the binding of c-Myc to wild-type oligonucleotides that
contain the sequence for the c-Myc binding site from the
HSP90alpha promoter by EMSA or not. As shown in
Figure 3C, we confirmed that the nuclear extract isolated
from HepG2-pcDNA3 and HepG2-pcDNA3-X cells all
induced an electromobility shift when a labeled wild-type
Figure 2 HBx upregulates Hsp90a expression by activating c-Myc. (A) Lysates from stable cell lines, HepG2-pcDNA3 (lane 1) and HepG2-
pcDNA3-X (lanes 2-4) after either mock treatment (lanes 1-3) or treatment with 200 nM U0126 (lane 4) for 4 h were prepared, and the protein
levels of c-Myc, ERK1/2 and phosphor-ERK-1/2 were detected by Western blot analysis. GAPDH was included as an internal control. (B) Total RNA
purified from HepG2-pcDNA3 (lane 1) and HepG2-pcDNA3-X (lanes 2-4) after either mock treatment (lanes 1-3) or treatment with 5 mM 10058-
F4 (lane 4) for 24 h was subjected to RT-PCR to measure the RNA level of c-Myc, HBx and GAPDH. (C) Western blot analysis was performed to
measure the levels of c-Myc, HBx and GAPDH in the cells prepared as described above. (D) HepG2-pcDNA3-X cells were transfected with 100 nM
of either control siRNA, c-Myc siRNA or in a combination and Western blotting analysis was performed.
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encompassing the 5’ flanking region of the human the Hsp90a promoter and the reporter constructs used. (B) Cells were cotransfected with or
without 1 μg of pcDNA3 or pcDNA3-X plasmid, 2 μg of Hsp90a promoter-luciferase reporter construct, and and 2 μgo fb-galactosidase reporter
plasmid by the LipofecAMINE method. Cells were cultured in 10% FBS medium for 24 h. Luciferase activity and b-galactosidase activity were
assayed by using the luciferase and b-galactosidase enzyme assay system. Luciferase activity was normalized with the b-galactosidase activity in
cell lysates. Error bars indicate standard deviations (SD) obtained from three different experiments prepared in triplicate. (C) The nuclear extract
isolated from HepG2-pcDNA3 (lane 1-3) and HepG2-pcDNA3-X (lanes 4-6) cells incubated with [g
-32P]ATP-labeled oligonucleotides corresponding
to the wt c-Myc binding site of the Hsp90a promoter. Competition was performed using unlabeled wt oligo or mutant oligo. Each sample was
electrophoresed in a 4% nondenaturing polyacrylamide gel in 0.5 × Tris-borate EDTA buffer at 250 V for 20 min. The gel was dried and
subjected to autoradiography.
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levels of the shifted bands in the nuclear lysates from
HepG2-pcDNA3 cells were lower than those for the
nuclear lysates from HepG2-pcDNA3-X cells. Moreover,
the formation of an electrophoretically retarded complex
was inhibited when an unlabeled wild-type oligonucleo-
tide or mutant-type oligonucleotides was introduced.
These results suggest that HBx regulates c-Myc-mediated
transcription of the HSP90alpha gene.
HSP90alpha up-regulation by HBx increases cellular
invasion ability
It has been described that increased HSP90alpha expres-
sion is strongly correlated with enhanced cell invasive-
ness in vitro and tumor progression in vivo [19-21].
Therefore, we finally examined whether the increased
HSP90alpha by HBx affects cell invasiveness in vitro.
Each cell line was either left untreated or treated with
10058-F4 for 24 h and subjected to the transwell inva-
sion assay. As shown in Figure 4, the invasion capacity
of HBxexpressing cells was increased when compared
with HepG2 and HepG2-pcDNA3 cells. Moreover, the
invasion ability of HBx-expressing cells was dramatically
decreased in the presence of 10058-F4. Therefore, we
prove that HBx-mediated HSP90alpha up-regulation
increases cell invasion ability in vitro.
Discussion
HSP90 is of interest because of its importance in main-
taining the conformation, stability and function of key
oncogenic proteins involved in signal transduction path-
ways leading to proliferation, cell cycle progression and
apoptosis, as well as other features of the malignant
phenotype such as invasion, angiogenesis and metastasis
[27].
Several recent studies provided consistent evidence for
ar o l eo fH S P 9 0 a l p h ai s o f o r mi nt u m o ri n v a s i v ea n d
metastatic phenotypes [19-22]. Transfection of HSP90al-
pha cDNA into invasive carcinoma cells led to signifi-
cant enhancement of their invasive capacity in vitro
[21], and activation of HSP90alpha resulted in increasing
of malignant potentials of tumor cell lines [22]. In addi-
tion, up-expression of HSP90alpha during tumor devel-
opment was observed in a variety of different tumor
types, including HCC and is closely associated with a
poor prognosis and resistance to therapy [28]. There-
fore, knowledge of the molecular mechanism that acti-
vates its expression or function is of primary importance
in understanding the process of tumor invasion. Here,
we further demonstrate that HBx induces c-Myc expres-
sion by activation of Ras/Raf/ERK1/2 cascades, which in
turn results in activation of the c-Myc-mediated
HSP90alpha promoter and subsequently upregulation of
the HSP90alpha expression, leading to the increased
invasive potential of HBx-expressing cells.
It is well known that HBx mediates the activation of
signal transduction pathways such as the Ras/Raf/ERK1/
2 cascades, leading to the induction of c-myc [29]. The
c-myc proto-oncogene is involved in the control of cell
cycle progression, proliferation, metabolism, and apopto-
sis [30]. c-Myc protein is a transcription factor that
functions via heterodimerization with MAX, a related
protein that, like c-Myc, contains basic, helix-loop-helix
and leucine zipper domains but lacks the transactivation
domain present in the amino terminus of c-Myc [31].
MYC/MAX complexes stimulate transcription of target
genes containing the MYC/MAX binding site (E-box) or
specific non-canonical elements in their regulatory
regions [32]. The c-myc proto-oncogene encodes a ubi-
quitous transcription factor involved in the control of
cell growth and differentiation and is implicated in indu-
cing hepatocarcinoma tumourigenesis [33]. Understand-
ing the function of c-myc and its role in cancer depends
upon the identification of c-myc target genes. The find-
ings of Teng et al [26] that c-myc directly activates
HSP90alpha transcription suggest that by induction of
HSP90alpha c-myc may control the activity of multiple
signal pathways involved in cellular transformation.
Recently, several studies showed that the increased tran-
scription of HSP90alpha in tumour cells is due to higher
expression of the protooncogenes HER2, c-Myc, k-ras
and other genes is crucial to tumourigenesis [34,35].
Although HBx has been reported to be associated with
HCC, there is no confirmative report of transcription
Figure 4 HBx increases cell invasion ability. Matrigel invasion
assay of HepG2-pcDNA3 and HepG2-pcDNA3-X cells. Cells (1 × 10
6)
were resuspended in conditioned medium and added to the upper
compartments of matrigel invasion chambers supplemented with or
without 5 mM 10058-F4 for 24 h. The total number of cells that
invaded to the underside of the filters was counted. The values
obtained were calculated by averaging the total number of cells
from three filters. As a control, a parallel experiment was performed
using the device with uncoated membrane. The results represent
means of triplicates; * statistically different from control at P < 0.05.
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which is related to invasion and metastasis of HCC. The
promoter region of HSP90alpha gene has a c-Myc bind-
ing site and plays an important role in HSP90alpha gene
activation. Thus, it is possible to speculate that HBx up-
regulates HSP90alpha expression by elevating the activ-
ity of transcriptional factor c-Myc.
The findings presented here clearly show that HBx
up-regulates HSP90alpha expression by inducing the
expression of c-Myc in HBx-transfected cells that
express HBx transcripts (Figure 2A and 2B). Moreover,
the increased expression of HSP90alpha in the presence
of HBx could be completely inhibited by treatment with
c-Myc inhibitor 10058-F4 or introducing a specific-
siRNA (Figure 2C).
Teng et al [26] reported that there is an E-box site
(CACGTG) in the 5’ promoter of HSP90alpha gene that
binds c-Myc, which is located the DNA sequence
between bases -1104 and -998, and that the HSP90alpha
promoter-derived oligonucleotide can specifically bind
to c-Myc, as assayed by EMSA. In addition, the mutated
HSP90alpha promoter, in which the E-box is destructed
by point mutations by changing the DNA sequence
from CACGTG to CACCTG in c-Myc binding site of
the HSP90alpha promoter, showed affect on transactiva-
tion of c-Myc and loss response to HBx with the wild-
type promoter, as measured by a luciferase reporter
assay. Furthermore, HSP90alpha mRNA and protein
levels are elevated in response to c-Myc induction in
HBx-transfected cells (Figure 1A and 1B). HBx is known
to activate c-Myc transcriptional activity through ERK1/
2. Therefore, it is possible to speculate that HBx may
activate the HSP90alpha gene via up-regulation of c-
Myc activity since HSP90alpha promoter contains the
binding motifs of the c-Myc complex.
In this study, we observedt h a to v e r e x p r e s s i o no f
HSP90alpha enhanced invasive activity of HBx-expres-
sing cells (Figure 4), demonstrating the oncogenic prop-
erty of HSP90alpha when its expression is increased.
This upregulation of the metastatic abilities of tumor
cells was corroborated by the Matrigel invasion assays,
in which HBx-expressing cells also displayed increased
invasive potential. In addition, treatment with c-Myc
inhibitor 10058-F4 or siRNA experiments to repress the
endogenous HSP90alpha levels in HBx-expressing cells
decreased their invasion activity (Figure 4). These results
are consistent with the role of increased HSP90alpha
levels by HBx contributing to malignant phenotype.
Conclusion
In summary, we conclude that HBx up-regulates
HSP90alpha expression by inducing the c-Myc-mediated
HSP90alpha promoter activation. The incressed
HSP90alpha expression results in inducing cell invasion
of the HBx-expressing cells. In addition, Repression of
endogenous c-Myc expression by siRNA significantly
reduces HSP90alpha expression and the invasive capa-
city of HBx-expressing cells. Therefore, the present
study suggests that HBx plays a role during the late
steps of tumor development and metastasis by increas-
ing invasion ability from the surrounding cells and
migration outside of the primary tumor site. This study
provides a new clue for understanding the role of HBx
during HCC progression, unveiling potential new target
in the therapy against HBV-related HCC.
Materials and methods
Cell culture
Human hepatocarcinoma cell lines, HepG2, were
obtained from Foundation Institute, Chinese Academy
of Medical Sciences. Stable cell lines, HepG2-pcDNA3
and HepG2-pcDNA3-X, were established by transfec-
tion with either an empty vector pcDNA3 or pcDNA3-
X encoding the corresponding full-length HBx
sequence (nt1374-1838) as described previously (24),
followed by selection with 500 mg/ml G418 (Gibco-
BRL, NY, USA). All cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco-BRL) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 μg/ml streptomycin, 5 mmol/L L-
glutamine and 200 μg/ml G418 at 37°C in a humidified
chamber with 5% CO2.
Semiquantitative RT-PCR
Total cellular RNA was extracted from HepG2 cells using
Trizol (Invitrogen). DNase I (Promega)-digested RNA
(2 μg) was reverse transcribed with the corresponding anti-
sense primer. One-quarter of the reversetranscribed RNA
was amplified with Taq DNA polymerase (Promega) (94°C
for 2 min; 35 cycles of 94°C for 30 s, 58°C for 20 s, 72°C
for 30 s, 72°C for 5 min) using the sense primers, 5’-AA
ACACCTGGAGATAAA CCC-3’,5 ’-TTCGGGTAGT
CGAAAACCAG-3’,5 ’-ACC GAATTCCCATGGCTGC
T-3’ and 5’-ACCACAGTCCA TGCCATCAC-3’; and anti-
sense primers, 5’-GTATCAT CAGCAGTAGGGTCA-3’,
5’-CAGCAGCTCGAATTTC TTCC-3’,5 ’-AACTCT
AGATGATTAGGCAGAGGT-3’ and 5’-TACAGCA
ACAGGGTGGTGGA-3’ for HSP90alpha, c-Myc, HBx
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
respectively. PCR products were separated by 1.8% agarose
gel electrophoresis, then scanned and analyzed by VDS
imagemaster system (Pharmacia).
Western blot analysis
Cells were homogenized in buffer containing 50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 0.02% NaN3,1 0 0μg/
mL PMSF, 1 μg/mL aprotinin, and 1% Triton X-100.
Protein concentration of cell extracts was measured
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Rad). In all, 20 μg of cell lysates were separated by SDS-
polyacrylamide gel electrophoresis and transferred onto
a nitrocellulose membrane (Hybond PVDF, Amersham).
The membranes were blotted for 60 min at room tem-
perature with non-fat dry milk (5%) in TBS containing
0.05% Tween-20 and were then incubated with specific
primary antibodies: rabbit polyclonal anti-human
HSP90alpha antibody (Cell Signaling Technology, USA,
1:1000), mouse monoclonal anti-human c-Myc antibody
(Santa Cruz, USA, 1:1000.), mouse monoclonal antihu-
man HBx antibody (Roche, USA, 1:500), mouse mono-
clonal anti-GAPDH antibody (Sigma, USA, 1:1000)
overnight at 4°C. Detection was performed using a sec-
ondary horseradish peroxidase-linked antimouse and
rabbit antibody, and an enhanced chemiluminescence
system (Amersham).
ERK activity assay
ERK activation was determined with a fast-activated,
cell-based, enzyme-linked immunosorbent assay kit
(Active Motif) according to the manufacturer’s instruc-
tions. Briefly, cultured cells placed in 96-well plates
were further cultured for 3 days and then treated with
or without U0126 (the ERKs inhibitor) (Calbiochem).
The inhibitors were added 1 hour before stimulation
with culture medium and at stimulation. At the indi-
cated times, the cells were fixed with 4% formaldehyde
for 20 minutes, extensively washed, and incubated with
a specific antiphosphorylated ERK1/2 antibody, followed
by incubation with a secondary horseradish peroxidase-
conjugated antibody. Phosphorylated ERK1/2 levels
were quantified with a colorimetric readout and are
expressed as the absorbance at 450 nm measured in
each well.
RNA interference
Both c-Myc siRNA vector (pGB-c-Myc) and negative
control siRNA vector (pGB-control) were purchased
from BioVision Biotechnology. Cells (2 × 10
6)w e r e
transfected with 100 nM of siRNA using Lipofectamine
2000 (Invitrogen) in Opti-MEM I reduced serum med-
ium (Invitrogen) for 6 h. The medium was removed and
replaced with fresh DMEM supplemented with 10% FBS
serum. Cells were harvested 72 h after transfection for
Western blotting analysis.
Electrophoretic mobility shift assay (EMSA)
The nuclear extracts were prepared from treated and
control HepG2-pcDNA3-X cells using a nuclear extrac-
tion kit (Active Motif). EMSA were performed using gel
shift assay system kit (Promega) according to the manu-
facturer’s instructions. Briefly, double-stranded oligonu-
cleotides containing the consensus sequences 5’-
GGGGCCCACGTGGCTGCTAGTTT-3’ (wild-type
HSP90alpha c-Myc binding site) were end-labeled with
[g
-32P] ATP (3000 Ci/mmol; Amersham Pharmacia Bio-
tech, UK) using T4 polynucleotide kinase and used as
probes for EMSA. Competition was also performed
using either the unlabeled wild-type oligonucleotide or a
mutant oligonucleotide 5’-GGGGCCCACCTGGCTGC-
TAGTTT-3’ (mutant oligo). Nuclear extract proteins (2
μg) were preincubated with the gel shift binding buffer
[4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM
dithiothreitol, 50 mM NaCl, 10 mM Tris-HCl (pH 7.5),
and 0.05 mg/ml poly (deoxyinosine-deoxycytosine)] for
10 min and then incubated with the labeled probe for
20 min at room temperature. Each sample was electro-
phoresed in a 4% nondenaturing polyacrylamide gel in
0.5 × TBE buffer at 250V for 20 min. The gel was dried
and subjected to autoradiography.
Promoter assay
The genomic region flank of the HSP90alpha gene promo-
ter (GenBank Accession No. U25822) was obtained from
genomic DNA of HepG2 cells by PCR amplification using
ap r i m e rs e t :5 ’-GACGCTCGATGCTCGAGCCTGGG
GGACCAAG-3’ (forward/XhoI) and 5’-CGTTAAGCGCC
TCCGCCCTGCACCCCCA-3’ (reverse/HindIII), and the
sequence was verified by sequencing. To generate the
reporter construct driven by HSP90alpha promoter, a
~1.4-kb fragment containing 1430 bp 5’ upstream of tran-
scription start site was subcloned into the XhoI-HindIII
sites of the luciferase reporter vector, pGL3-Luc (Pro-
mega), to create the HSP90alpha-Luc1430 construct. The
HSP90alpha-Luc1430Mut construct was made by chan-
g i n gt h es e q u e n c ef r o mC A C G T Gt oC A C C T Gi nt h e
HSP90alpha-Luc1430 construct by using the Quick
Change Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA). HepG2 cells were seeded at 1 × 10
5 cells/60
mm diameter plate and grown overnight. Cells were
cotransfected with or without 1 μgo fp c D N A 3o r
pcDNA3-X plasmid, 2 μg of HSP90alpha promoterlucifer-
ase reporter constructs, and 2 μgo fb-galactosidase repor-
ter plasmid (Promega) by the LipofecAMINE method
(Invitrogen). Cells were cultured in 10% FBS medium for
24 h. Luciferase activity and b-galactosidase activity were
assayed by using the luciferase and b-alactosidase enzyme
assay system (Promega). Luciferase activity was normalized
with the b-alactosidase activity in cell lysate and calculated
as an average of three independent experiments.
In vitro invasion assay
In vitro invasion assay was performed using 24-well
Transwell unit with polycarbonate filters (Corning
Costar, Cambridge, MA). The cells were placed in
the upper part of the Transwell, incubated for indicated
time, fixed with methanol, and stained with hematoxylin
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Page 8 of 10for 10 min followed briefly by eosin. Cells in the upper
chamber were removed by cotton swab and the cells
that invaded through the Matrigel and were located on
the underside of the filter (16 fields/filter) were counted
under a microscope. The results are expressed as fol-
lows: % invasion index (the number of cells migrating
through the Matrigel-coated membrane/the number of
cells migrating through the uncoated control mem-
brane) × 100. The experiment was repeated three times
prepared with duplicate.
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